LEADER 01577nam  2200409   450 
001 9910707890003321
005 20161130145030.0
035   $a(CKB)5470000002467655
035   $a(OCoLC)964630890
035   $a(EXLCZ)995470000002467655
100   $a20161130d2016      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrug compounding, FDA has taken steps to implement compounding law, but some states and stakeholders reported challenges : report to Congressional Committees
210  1$a[Washington, D.C.] :$cUnited States Government Accountability Office,$d2016.
215   $a1 online resource (iii, 65 pages) $ccolor illustrations
300   $a"November 2016."
300   $a"GAO-17-64."
320   $aIncludes bibliographical references.
517   $aDrug compounding, FDA has taken steps to implement compounding law, but some states and stakeholders reported challenges 
606   $aDrugs$xDosage forms
606   $aPharmaceutical policy
606   $aDrug control
606   $aDrugs$xLaw and legislation
615  0$aDrugs$xDosage forms.
615  0$aPharmaceutical policy.
615  0$aDrug control.
615  0$aDrugs$xLaw and legislation.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707890003321
996   $aDrug compounding, FDA has taken steps to implement compounding law, but some states and stakeholders reported challenges : report to Congressional Committees$93354163
997   $aUNINA